Accessmedicalsp. z o.o.

Physiotherapeutical activities

KRS: NIP: REGON:

Overview

Status
Active
Registry date
2018-09-27
Share capital
5 000,00 PLN
Registered address
ul. Zajęcza 15, 00-351 Warszawa, Poland

Financials

Revenue history (in k)

Filing timeliness

No financial statement for 2022 – the filing deadline has passed. 3 of 3 financial statements were filed late (the longest delay 733 days for 2019).

  • 2022not filed
  • 202118/10/2022
  • 202018/10/2022
  • 201918/10/2022
Filed on timeDelayFiling deadline

Data and insights are generated automatically from financial statements – they may contain errors and are neither a credit assessment nor business advice.

Statistics

How the company ranks by revenue within its industry, region and across Poland in 2021.

Results vs industry

Revenue
This companyUSD 60.00kMedianUSD 173.20kAverageUSD 605.71k
Net profit
This companyUSD -39.25kMedianUSD 4.13kAverageUSD 75.80k
Operating costs
This companyUSD 98.68kMedianUSD 161.79kAverageUSD 500.80k
Assets
This companyUSD 199.14kMedianUSD 67.85kAverageUSD 409.30k

Authorized Representatives

Marek Czapka – President of the Management Board

Manner of representation

In the case of a one-person management board, the member of the management board makes declarations on behalf of the company. In the case of a management board consisting of two or more persons, joint action by two members of the management board or by one member of the management board jointly with a commercial proxy is required to make declarations on behalf of the company.

Ownership

OwnerSharesShare valueStake
Ryszarda Czapkaage 78
95$1,283.0995%
Others
5$67.535%

Beneficial owners

Person

Debt

No entries in the National Debtors Register (KRZ).

Public aid

20 public aid cases recorded, with a total value of $195,289.

PurposeGross amount
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$10,867
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,294
Aid compensating for the negative economic consequences of COVID-19, granted in limited amounts
$1,294

Competitors

FAQ

Last updated: 2026-04-09